Wills & Planned Gifts

Many donors take steps to include the Neuroendocrine Tumor Research Foundation in their estate plans. Gifts of this nature, or planned gifts, are legally arranged during the donor’s lifetime but are not usually dispersed until a later date.

For donors, a planned gift through a will or living trust is an effective and affordable way to make a major financial contribution and have a lasting impact on NETRF.  Many planned gifts can also have tax advantages.

Tell us about your planned gift to:

  • Receive our monthly eUpdate newsletter.
  • Be recognized in our Annual Report and other donor listings.
  • Receive special invitations to events with NETRF leadership and scientists.
  • Share your gift story and be profiled in publications and on our website.

Ways to make a planned gift

We recommend that you contact your financial advisor and attorney to guide you in making this type of gift. Recognizing that this is a very sensitive topic that deserves care and consideration, we provide the information below as a resource for you.

Contact Susan Payson, susan.payson@netrf.org to learn more about establishing a legacy to support our mission.

Notify us using the form below if you have already arranged for a planned gift or a bequest so that NETRF is aware of your wishes and can celebrate your generosity today!

Sample language

What follows is suggested language you may choose to include NETRF in your will or estate plan.  Please work with your financial advisor and/or attorney in making this intention.  

Unrestricted Gift:  A gift that can be used where need is greatest.

I give, devise, and bequeath to the Neuroendocrine Tumor Research Foundation, 31 St. James Avenue, Suite 365, Boston, Massachusetts 02116, (insert dollar amount, percentage amount, or description of property) to be used for its general purposes. Neuroendocrine Tumor Research Foundation Tax ID: 20-1945347.

Residuary Bequest:  Leaves any remainder after all other distributions have been paid.

I give, devise, and bequeath to the Neuroendocrine Tumor Research Foundation,  31 St. James Avenue, Suite 365, Boston, Massachusetts 02116, (insert percentage amount) percent of the residue of my estate to be used for its general purposes. Neuroendocrine Tumor Research Foundation Tax ID: 20-1945347.

Contingency Gift:  Takes effect only if a primary intention cannot be met.

In the event that (insert name) predeceases me, I give, devise, and bequeath his/her bequest or share to the Neuroendocrine Tumor Research Foundation, 31 St. James Street, Suite 365, Massachusetts 02116, to be used for its general purposes. Neuroendocrine Tumor Research Foundation Tax ID: 20-1945347.

Contact NETRF about Planned Giving

If you would like to learn more about matching gifts, planned gifts, and bequests, or gifts of stock gifts, please fill out the form below. Please add any comments to give us context about your interest or request.

Ask a question about giving

The latest in NET News

The 2021 Virtual NET Research Symposium – Summary/Recap

The fourteenth annual NETRF Research Symposium successfully concluded last month with over 300 registered virtual attendees participating from around the globe for the second year in a row. The meeting included nearly 60 talks and posters representing the cutting edge of NET research where investigators reported their latest data and discoveries to share and discuss with colleagues. This year posters were available for viewing over the three days preceding the two-day meeting, resulting in over 300 poster views and ample time for discussions. Over 95% of registrants attended the two-days of talks and live discussions while the recorded talks and posters were viewed by over 100 more attendees over the following week.

NETRF Announces Changes to its Board of Scientific Advisors

Dr. Thirlwell, the Mireille Gillings Professor of Cancer Genomics at the University of Exeter Medical School will assume the role in January of 2022. She is internationally renowned for advancing NET research, the clinical management of NETs and the integrated genomic analysis of cancer.